Warning letter
Kirk Pharmaceuticals, LLC [ARCHIVED]: warning letter of Feb 4, 2010
FDA warning letter 77747 · Florida District Office
Key facts
| Reference number | 77747 |
|---|---|
| Company | Kirk Pharmaceuticals, LLC [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 4, 2010 |
| Posted date | Feb 4, 2010 |
| Issuing office | Florida District Office |
| Product type | Drugs |
| CFR sections cited | 211.180(e), 211.22(d), 211.192, 211.110(b), 211.165(f), 211.165(e) |
| Inspection city | Fort Lauderdale |
| Inspection ZIP | 33309 |
| Inspection start date | Jun 17, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: